<p>Skye Bioscience, Inc.（納斯達克代碼：SKYE - 獲取免費報告）的股票在目前覆蓋該公司的六家研究機構中獲得了平均 “買入” 的推薦，MarketBeat Ratings 報告稱。六位投資分析師對該股票給予了買入推薦。在過去一年中，覆蓋該股票的經紀人給出的平均一年目標價格為 18.67 美元。</p>
<p>獲取 <strong>Skye Bioscience</strong> 的提醒：</p>
<ul>
<li>MarketBeat 週報 – 10/7 - 10/11</li>
</ul>
<p>另外，William Blair 在週五的一份研究報告中開始覆蓋 Skye Bioscience 的股票。他們對該公司的評級為 “跑贏大盤”。</p>
<p><strong>查看我們關於 Skye Bioscience 的最新股票報告</strong></p>
<h2>機構投資者對 Skye Bioscience 的看法</h2>
<ul>
<li>不要忽視 Skye Bioscience——這款減肥藥可能會飆升</li>
</ul>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Virtu Financial LLC 在第四季度購買了 Skye Bioscience 的新股份，價值約 29,000 美元。Wells Fargo &amp; Company MN 在第四季度將其在 Skye Bioscience 的持倉提高了 49.0%。Wells Fargo &amp; Company MN 現在擁有該公司 11,199 股股票，價值 32,000 美元，此前在此期間又購買了 3,684 股。Two Sigma Advisers LP 在第四季度購買了 Skye Bioscience 的新股份，價值約 32,000 美元。Jane Street Group LLC 在第三季度購買了 Skye Bioscience 的新股份，價值約 48,000 美元。最後，Squarepoint Ops LLC 在第四季度購買了 Skye Bioscience 的新股份，價值約 38,000 美元。21.09% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Skye Bioscience 價格表現</h2>
<p>週五，SKYE 的股票開盤價為 2.68 美元。該公司的 50 日簡單移動平均線為 3.02 美元，200 日簡單移動平均線為 3.17 美元。Skye Bioscience 的 12 個月最低價為 2.31 美元，最高價為 19.41 美元。</p>
<h2>關於 Skye Bioscience</h2>
<p>（獲取免費報告）</p>
<ul>
<li>3 只高風險、高回報的微型股你不應忽視</li>
</ul>
<p>Skye Bioscience, Inc. 是一家臨牀階段的製藥公司，發現、開發和商業化基於大麻素的分子用於治療傳染病。該公司的主要產品候選藥物是用於治療青光眼和眼內高壓的 SBI-100。它還在開發 SBI-200，以治療和管理各種眼病，包括葡萄膜炎、乾眼症、黃斑變性和糖尿病視網膜病變。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票而非 Skye Bioscience</li>
<li>恒生指數是什麼？</li>
<li>3 只值得關注的股票：解鎖明天的贏家</li>
<li>股票平均計算器</li>
<li>為什麼聰明的投資者在關注這 3 只被低估的股票</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>3 只突破增長潛力的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0tZRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0tZRQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Skye Bioscience 嗎？</h2>
<p>在你考慮 Skye Bioscience 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Skye Bioscience 並不在名單上。</p>
<p>雖然 Skye Bioscience 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SKYE

<p>Skye Bioscience, Inc.（納斯達克代碼：SKYE）獲得了六家研究公司的平均 “買入” 推薦。平均一年目標價為 18.67 美元。最近，William Blair 開始覆蓋，並給予 “跑贏大盤” 的評級。機構投資者增加了他們的持股，21.09% 的股票由對沖基金持有。目前，股票交易價格為 2.68 美元，12 個月的價格區間為 2.31 美元至 19.41 美元。Skye Bioscience 專注於基於大麻素的各種眼病治療，包括青光眼</p>

<p>Shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average recommendation of &#34;Buy&#34; from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $18.67.</p>
<div class="lb-trans"><p>Skye Bioscience, Inc.（納斯達克代碼：SKYE - 獲取免費報告）的股票在目前覆蓋該公司的六家研究機構中獲得了平均 “買入” 的推薦，MarketBeat Ratings 報告稱。六位投資分析師對該股票給予了買入推薦。在過去一年中，覆蓋該股票的經紀人給出的平均一年目標價格為 18.67 美元。</p>
</div><p>Get <strong>Skye Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Skye Bioscience</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 10/7 - 10/11</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 10/7 - 10/11</li>
</ul>
</div><p>Separately, William Blair started coverage on shares of Skye Bioscience in a research report on Friday. They set an &#34;outperform&#34; rating for the company.</p>
<div class="lb-trans"><p>另外，William Blair 在週五的一份研究報告中開始覆蓋 Skye Bioscience 的股票。他們對該公司的評級為 “跑贏大盤”。</p>
</div><p><strong>View Our Latest Stock Report on Skye Bioscience</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Skye Bioscience 的最新股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Skye Bioscience</h2>
<div class="lb-trans"><h2>機構投資者對 Skye Bioscience 的看法</h2>
</div><ul>
<li>Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar</li>
</ul>
<div class="lb-trans"><ul>
<li>不要忽視 Skye Bioscience——這款減肥藥可能會飆升</li>
</ul>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Skye Bioscience in the 4th quarter worth about $29,000. Wells Fargo &amp; Company MN lifted its position in shares of Skye Bioscience by 49.0% in the 4th quarter. Wells Fargo &amp; Company MN now owns 11,199 shares of the company's stock worth $32,000 after purchasing an additional 3,684 shares during the period. Two Sigma Advisers LP purchased a new stake in shares of Skye Bioscience in the 4th quarter worth about $32,000. Jane Street Group LLC purchased a new stake in shares of Skye Bioscience in the 3rd quarter worth about $48,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Skye Bioscience in the 4th quarter worth about $38,000. 21.09% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Virtu Financial LLC 在第四季度購買了 Skye Bioscience 的新股份，價值約 29,000 美元。Wells Fargo &amp; Company MN 在第四季度將其在 Skye Bioscience 的持倉提高了 49.0%。Wells Fargo &amp; Company MN 現在擁有該公司 11,199 股股票，價值 32,000 美元，此前在此期間又購買了 3,684 股。Two Sigma Advisers LP 在第四季度購買了 Skye Bioscience 的新股份，價值約 32,000 美元。Jane Street Group LLC 在第三季度購買了 Skye Bioscience 的新股份，價值約 48,000 美元。最後，Squarepoint Ops LLC 在第四季度購買了 Skye Bioscience 的新股份，價值約 38,000 美元。21.09% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Skye Bioscience Price Performance</h2>
<div class="lb-trans"><h2>Skye Bioscience 價格表現</h2>
</div><p>Shares of SKYE opened at $2.68 on Friday. The firm has a fifty day simple moving average of $3.02 and a two-hundred day simple moving average of $3.17. Skye Bioscience has a twelve month low of $2.31 and a twelve month high of $19.41.</p>
<div class="lb-trans"><p>週五，SKYE 的股票開盤價為 2.68 美元。該公司的 50 日簡單移動平均線為 3.02 美元，200 日簡單移動平均線為 3.17 美元。Skye Bioscience 的 12 個月最低價為 2.31 美元，最高價為 19.41 美元。</p>
</div><h2>About Skye Bioscience</h2>
<div class="lb-trans"><h2>關於 Skye Bioscience</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高風險、高回報的微型股你不應忽視</li>
</ul>
</div><p>Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.</p>
<div class="lb-trans"><p>Skye Bioscience, Inc. 是一家臨牀階段的製藥公司，發現、開發和商業化基於大麻素的分子用於治療傳染病。該公司的主要產品候選藥物是用於治療青光眼和眼內高壓的 SBI-100。它還在開發 SBI-200，以治療和管理各種眼病，包括葡萄膜炎、乾眼症、黃斑變性和糖尿病視網膜病變。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Skye Bioscience</li>
<li>What is the Hang Seng index?</li>
<li>3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today</li>
<li>Stock Average Calculator</li>
<li>Why Smart Investors Are Watching These 3 Undervalued Stocks</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>3 Stocks Breaking Out with More Growth Potential Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票而非 Skye Bioscience</li>
<li>恒生指數是什麼？</li>
<li>3 只值得關注的股票：解鎖明天的贏家</li>
<li>股票平均計算器</li>
<li>為什麼聰明的投資者在關注這 3 只被低估的股票</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>3 只突破增長潛力的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0tZRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SKYE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Skye Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Skye Bioscience 嗎？</h2>
</div><p>Before you consider Skye Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Skye Bioscience 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Skye Bioscience 並不在名單上。</p>
</div><p>While Skye Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Skye Bioscience 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Skye Bioscience, Inc.（納斯達克股票代碼：SKYE）獲得券商的平均 “買入” 評級